請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8034
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉仁沛 | |
dc.contributor.author | Chen-Fang Chen | en |
dc.contributor.author | 陳瑱芳 | zh_TW |
dc.date.accessioned | 2021-05-19T18:03:42Z | - |
dc.date.available | 2023-12-31 | |
dc.date.available | 2021-05-19T18:03:42Z | - |
dc.date.copyright | 2013-07-31 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-07-26 | |
dc.identifier.citation | 1. Basford K.E., Greenway D.R., McLachlan G.J. and Peel D. (1997). Standard errors of fitted component means of normal mixtures, Computational Statistics. 12(1):1-17.
2. Buyse, M., Loi, S., van’t Veer, L., et al. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer, Journal of the National Cancer Institute, 98, 1183-1192. 3. Casciano D.A. and Woodcock J. (2006). Empowering microarrays in the regulatory setting, Nature Biotechnology. 24: 1103. 4. Chow S.C. and Liu J.P. (2004). Design and Analysis of Clinical Trials, 2nd Ed., John Wiley and Sons, 3rd Ed., New York, USA. 5. Collett D. (2003). Modeling Survival Data in Medical Research, 2nd Ed., Chapman and Hall, London, UK. 6. Dalton W.S. and Friend S.H. (2006). Cancer Biomarkers – an invitation to the table, Science. 312: 1165-8. 7. Dempster A.P., Laird N.M. and Rubin D.B. (1977). Maximum Likelihood from Incomplete Data via the EM Algorithm, Journal of the Royal Statistical Society. Series B (Methodological). 39(1): 1-38 8. Efron B. and Tibshirani R.J. (1993). An Introduction to the Bootstrap, Chapman and Hall, New York, USA. 9. Fleiss J.L., Levin B. and Paik M.C. (2003). Statistical Methods for Rates and Proportions, 3rd Ed. John Wiley and Sons, New York. 10. Freidlin B. and Simon R. (2005). Evaluation of randomized discontinuation design. Journal of Clinical Oncology. 23: 5094-5098. 11. Liu J.P. and Chow S.C. (2008). Issues on the diagnostic multivariate index assay and targeted clinical trials, Journal of Biopharmaceutical Statistics. 18: 167-182. 12. Liu J.P. and Lin J.R. (2008). Statistical methods for targeted clinical trials under enrichment design. Journal of the Formosan Medical Association.107: S35-S42. 13. Liu J.P., Lin J.R. and Chow S.C. (2009). Inference on treatment effects for targeted clinical trials under enrichment design. Pharmaceutical Statistics. 8: 356-370 14. Maitournam A. and Simon R. (2005). On the efficiency of targeted clinical trials. Statistics in Medicine. 24: 329-339. 15. McLachlan G.J. and Krishnan T. (1997). The EM algorithm and Extensions, Wiley, New York 16. McLachlan G.J. and Peel D. (2000). Finite Mixture Models, Wiley, New York, USA. 17. More, J.J., Garbow, B.S. and Hillstrom, K.E. (1980). User Guide for MINPACK-1, ANL-80-74. Argonne National Laboratory, Chicago. 18. Ravdin, P.M. and Chamness, G.C. (1995). The c-erbB-2 proto-oncogene as a prognostic and predictive markers in breast cancer: A paradigm for the development of other macromolecular markers-a review. Gene, 159, 19-27. 19. Romond, E.H., Perez, E.A., Bryant, J. et al. (2005). Trastuzumab plus chemotherapy for operable HER2-positive breast cancer, New England Journal of Medicine. 353: 1673-84. 20. Ng, S.K., McLachlan, G.J., Yau, K.K. W. and Lee, A.H. (2004). Modelling the distribution of ischaemic stroke-specific survival time using an EM-based mixture approach with random effects adjustment. Statistics in Medicine. 23: 2729-2744. 21. Seshadri, R., Figaira, E.A., Horsfall, D.J., McCaul, K., Setlur, V., and Kitchen, P. (1993). Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. Journal of Clinical Oncology. 11: 1936-1942. 22. Simon R. (2008). The use of genomics in clinical trial design. Clinical Cancer Research. 14: 5984-93. 23. Simon R. and Maitournam A. (2004). Evaluating the efficiency of targeted designs for randomized clinical trials. Clinical Cancer Research. 10: 6759- 6763. 24. Slamon, D.J., Leyland-Jones B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, New England Journal of Medicine. 344: 783-792. 25. U.S. FDA (1998). Decision Summary P980018. Rockville, Maryland, U.S.A. 26. U.S. FDA (2001). Decision Summary P980024/S001. Rockville, Maryland, U.S.A. 27. U.S. FDA (2004). Decision Summary P040030. Rockville, Maryland, U.S.A. 28. U.S. FDA (2005). The draft concept paper on Drug-Diagnostic Co-Development. The U.S. Food and Drug Administration, Rockville, Maryland, USA. 29. U.S. FDA (2006). Annotated Redlined Draft Package Insert for HerceptinR. The U.S. Food and Drug Administration, Rockville, Maryland, U.S.A. 30. U.S. FDA (2007a). Decision Summary k062694. Rockville, Maryland, U.S.A. 31. U.S. FDA (2007b). Draft Guidance on In Vitro Diagnostic Multivariate Index Assays. The U.S. Food and Drug Administration, Rockville, Maryland, USA. 32. U.S. FDA (2007c). Guidance on Gene Expression Profiling Test System for Breast Cancer Prognosis. The U.S. Food and Drug Administration, Rockville, Maryland, USA. 33. U.S. FDA (2007d). Guidance on Drug Metabolizing Enzyme Genotyping System. The U.S. Food and Drug Administration, Rockville, Maryland, USA. 34. The U.S. FDA (2007e). Decision Summary k062694, Rockville, Maryland, U.S.A. 35. The U.S. FDA (2011). Draft Guidance on In Vitro Companion Diagnostic Devices. The U.S. Food and Drug Administration, Rockville, Maryland, USA. 36. Varmus H. (2006). The new era in cancer research, Science. 312: 1162-5. 37. Wu C.F. (1983). On the convergence properties of the EM algorithm. The Annals of Statistics. 11: 95-103. 38. Zucker, D.M. and Spiegelman, D. (2004) Inference for the proportional hazards model with misclassified discrete-valued covariates, Biometrics. 60: 324–334. 39. Zucker, D. M. and Spiegelman, D. Corrected score estimation in the proportional hazards model with misclassified discrete covariates. Statistics in Medicine 2008, 27: 1911–1933. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8034 | - |
dc.description.abstract | 在傳統的臨床試驗中,納入和排除標準通常是基於一些臨床指標而未考量受試者的基因或基因的變異。在完成人類基因體計畫後,因可鑑別疾病的分子標的,進而發展出分子標的治療方法。但是分子標的鑑定的診斷試劑通常並非百分之百準確,所以納入標的臨床試驗的陽性診斷病人實際上有些可能並沒有此分子標的。因此,標的臨床試驗下之標的療法對於真正擁有分子標的之病人族群而言的療效估計值會有偏差。因此,我們提出對於真正擁有分子標的之病人配合標的療法之不偏推論的統計方法。在強化設計的臨床試驗及指數分佈及比例化風險迴歸模式下,我們提出利用EM演算法配合拔靴技術並考慮鑑定分子標的之診斷試劑的準確度,針對設限資料來進行處理效應之推論。並運用模擬研究加以評估所提出估計式與檢定方式的表現,及提出實例數據以說明方法的應用。 | zh_TW |
dc.description.abstract | For the traditional clinical trials, inclusion and exclusion criteria are usually based on some clinical endpoints, the genetic or genomic variability of the trial participants are not totally utilized in the criteria. After completion of the human genome project, the disease targets at the molecular level can be identified and can be utilized for the treatment of diseases. However, the accuracy of diagnostic devices for identification of such molecular targets is usually not perfect. Some of the patients enrolled in targeted clinical trials with a positive result for molecular target might not have the specific molecular targets. As a result, the treatment effect may be underestimated in the patient population truly with the molecular target. To resolve this issue, under the exponential distribution and the Cox-Proportional hazard model, we develop inferential procedures for the treatment effects of the targeted drug based on the censored endpoints in the patients truly with the molecular targets. Under an enrichment design, we propose using the EM algorithm in conjunction with the bootstrap technique to incorporate the inaccuracy of the diagnostic device for detection of the molecular targets on the inference of the treatment effects. A simulation study was conducted to empirically investigate the performance of the proposed methods. The impact of the simulation of the assumption for the proportional hazard model was also examined in the simulation study. Numerical examples illustrate the proposed procedures. | en |
dc.description.provenance | Made available in DSpace on 2021-05-19T18:03:42Z (GMT). No. of bitstreams: 1 ntu-102-D96621203-1.pdf: 774191 bytes, checksum: b28405b860b3d71c0be49b6d37a9d1af (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | Chapter 1 Introduction 1
1.1 Accuracy of Diagnostic Devices 4 1.2 Statistical Designs 8 1.3 Aims 10 Chapter 2 Literature Review 19 2.1 Efficiency of Enrichment Design 20 2.2 EM Algorithm 21 2.3 Convergence of EM Algorithm 23 2.4 Estimator of the Standard Error 23 Chapter 3 Statistical Inference under the Exponential Distribution Model 25 3.1 Current Methods 25 3.2 The Proposed Procedure 30 3.3 Numerical Example 35 Chapter 4 Statistical Inference under the Parametric Proportional Hazard Regression Model 39 4.1 Current Methods 39 4.2 The Proposed Procedure 42 Chapter 5 Simulation Studies 47 5.1 The Exponential Distribution Model 47 5.1.1 Simulation Procedure 47 5.1.2 Simulation Results 49 5.2 The Parametric Proportional Hazard Regression Model 50 5.2.1 Simulation Procedure 50 5.2.2 Simulation Results 52 Chapter 6 Discussion 67 REFERENCES 75 Appendix A Fortran Codes for Simulation 79 Appendix B Publish Papers 96 | |
dc.language.iso | en | |
dc.title | 強化設計標的臨床試驗下設限資料統計推論之研究 | zh_TW |
dc.title | A Study on Statistical Inference Based on Censored Data for Targeted Clinical Trials under Enrichment Design | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 周賢忠,季瑋珠,蕭金福,蔡政安,林志榮 | |
dc.subject.keyword | 標的臨床試驗,強化設計,設限資料,EM演算法, | zh_TW |
dc.subject.keyword | Targeted clinical trials,Enrichment design,Censored data,EM algorithm, | en |
dc.relation.page | 105 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2013-07-26 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 農藝學研究所 | zh_TW |
dc.date.embargo-lift | 2023-12-31 | - |
顯示於系所單位: | 農藝學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf | 756.05 kB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。